From epidemiology to molecular pathology: current research status and future prospects on the role of toxic metal exposure in the development and progression of bladder cancer
- 1Operating Room 1, First Hospital of Jilin University , ,
- 2Operating Room 1, Second Hospital of Jilin University , ,
Abstract
Bladder cancer remains a prevalent and lethal urinary malignancy, characterized by high recurrence rates and persistently poor prognosis for muscle-invasive disease. This clinical reality underscores the urgent need to identify modifiable risk factors. Epidemiological evidence from case-control and prospective cohort studies has established dose-dependent associations with arsenic and consistent tissue-specific accumulation of cadmium and chromium, while lead remains conditional on metabolic status. Nevertheless, substantial study heterogeneity persists, largely due to differences in exposure assessment methods, dose-response patterns, and confounding by smoking. A comprehensive synthesis integrating population-level findings with mechanistic insights remains conspicuously lacking. This review addresses this gap by critically evaluating the epidemiological associations, appraising sources of heterogeneity, and synthesizing current mechanistic understanding. The evidence points to a convergent model in which these metals trigger ROS-mediated oxidative stress and mitochondrial dysfunction as upstream initiating events, which aberrantly activate two midstream signaling branches—the ROS-dependent p38-MAPK/NF-κB and PI3K/AKT pathways promoting proliferation and survival, and the ROS-independent SUMOylation/TGF-β/Smad2/3 axis driving epithelial-mesenchymal transition. NRF2 exhibits stage-dependent duality with extensive pathway crosstalk, and these signals converge on downstream outcomes, including resistance to apoptosis, invasion, and metastasis. Beyond cancer cell-intrinsic effects, emerging evidence indicates that metal-induced signaling aberrations also remodel the tumor microenvironment through immune reprogramming, stromal activation, and metabolic shifts. Based on these insights, we propose a biomarker-guided, multi-tiered prevention framework spanning primary environmental control, secondary chemoprevention, and tertiary targeted therapy. Despite encouraging progress, critical knowledge gaps persist, particularly regarding multi-metal co-exposure, population-level mechanistic validation, and clinical translation. This review identifies these limitations and charts interdisciplinary research directions that integrate advanced exposure assessment, multi-omics, and rigorous clinical evaluation to bridge environmental exposure science and precision prevention of bladder cancer.
Related
- Stepwise Upregulation of Microglial Genes through the Slow Progression of Amyloid Pathology in Alzheimer’s Disease Model Mice
- CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression
- Dissemination of ESBL-producing Escherichia coli and carriage in the community worldwide: epidemiology, transmission pathways, molecular insights, and practical aspects
- Continuous Diagnostic Indices from BanffNET Automated Lesion Scores for Kidney Transplant Pathology: Development and Evaluation of a Diagnostic Prediction Model
- Comprehensive Molecular Profiling for Precision Diagnostics: Integrating Genomic, Proteomic, and Epigenetic Landscapes in Human Pathology
BibTeX
@article{li2026from,
title = {{From epidemiology to molecular pathology: current research status and future prospects on the role of toxic metal exposure in the development and progression of bladder cancer}},
author = {Danrui Li and Xu Sun and Tong Yu},
journal = {Frontiers in cell and developmental biology},
year = {2026},
month = oct,
doi = {10.3389/fcell.2026.1930640},
url = {https://europepmc.org/article/PMC/PMC13728351},
note = {CC BY},
}
RIS
TY - JOUR
TI - From epidemiology to molecular pathology: current research status and future prospects on the role of toxic metal exposure in the development and progression of bladder cancer
AU - Danrui Li
AU - Xu Sun
AU - Tong Yu
PY - 2026
DA - 2026/10/20
JO - Frontiers in cell and developmental biology
DO - 10.3389/fcell.2026.1930640
UR - https://europepmc.org/article/PMC/PMC13728351
AB - Bladder cancer remains a prevalent and lethal urinary malignancy, characterized by high recurrence rates and persistently poor prognosis for muscle-invasive disease. This clinical reality underscores the urgent need to identify modifiable risk factors. Epidemiological evidence from case-control and prospective cohort studies has established dose-dependent associations with arsenic and consistent tissue-specific accumulation of cadmium and chromium, while lead remains conditional on metabolic status. Nevertheless, substantial study heterogeneity persists, largely due to differences in exposure assessment methods, dose-response patterns, and confounding by smoking. A comprehensive synthesis integrating population-level findings with mechanistic insights remains conspicuously lacking. This review addresses this gap by critically evaluating the epidemiological associations, appraising sources of heterogeneity, and synthesizing current mechanistic understanding. The evidence points to a convergent model in which these metals trigger ROS-mediated oxidative stress and mitochondrial dysfunction as upstream initiating events, which aberrantly activate two midstream signaling branches—the ROS-dependent p38-MAPK/NF-κB and PI3K/AKT pathways promoting proliferation and survival, and the ROS-independent SUMOylation/TGF-β/Smad2/3 axis driving epithelial-mesenchymal transition. NRF2 exhibits stage-dependent duality with extensive pathway crosstalk, and these signals converge on downstream outcomes, including resistance to apoptosis, invasion, and metastasis. Beyond cancer cell-intrinsic effects, emerging evidence indicates that metal-induced signaling aberrations also remodel the tumor microenvironment through immune reprogramming, stromal activation, and metabolic shifts. Based on these insights, we propose a biomarker-guided, multi-tiered prevention framework spanning primary environmental control, secondary chemoprevention, and tertiary targeted therapy. Despite encouraging progress, critical knowledge gaps persist, particularly regarding multi-metal co-exposure, population-level mechanistic validation, and clinical translation. This review identifies these limitations and charts interdisciplinary research directions that integrate advanced exposure assessment, multi-omics, and rigorous clinical evaluation to bridge environmental exposure science and precision prevention of bladder cancer.
SN - 2296-634X
ER -